D3S-001: A KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities

D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Inhibits Nucleotide Cycling and Demonstrates Robust Preclinical and Clinical Activity Background Introduction The KRAS (Kirsten rat sarcoma viral oncogene homolog) gene mutation is one of the oncogenic drivers in various solid tumors (such as non-small cell lung cancer (NSCLC) an...

St. Jude Survivorship Portal: Sharing and Analyzing Large Clinical and Genomic Datasets from Pediatric Cancer Survivors

St. Jude Survivorship Portal: Sharing and Analyzing Large Clinical and Genomic Datasets from Pediatric Cancer Survivors

St. Jude Survivorship Portal: Analysis and Sharing of Large-Scale Clinical and Genomic Data of Pediatric Cancer Survivors Research Background In the United States, the five-year survival rate for childhood cancer has increased from about 60% in the 1970s to over 85% today. Despite the significant improvement in survival rates, these childhood cance...

Identification of Clonal Hematopoiesis Driver Mutations Through In Silico Saturation Mutagenesis

Introduction In the process of healthy hematopoiesis, a group of hematopoietic stem cells (HSC) contribute to all blood-related lineages. However, as we age, this process often leads to clonal hematopoiesis (CH), meaning the expansion of clones originating from a particular HSC, which then occupies a significant portion of blood cells and platelets...

Novel WRN Helicase Inhibitors Selectively Target Microsatellite-Unstable Cancer Cells

In the current field of tumor treatment, precision medicine continues to be a research hotspot and development trend. With the advancement of science and technology, we have begun to more accurately understand the characteristics of tumor cells and their dependencies for survival, in hopes of finding new therapeutic targets. Particularly, strategie...

ror2 regulates cellular plasticity in pancreatic neoplasia and adenocarcinoma

ror2 regulates cellular plasticity in pancreatic neoplasia and adenocarcinoma

Research Report: The Regulatory Role of ROR2 in Pancreatic Cancer Cell Plasticity Background Introduction Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease with most patients lacking the possibility of a cure. This is partly due to the difficulty in early detection. One of the characteristics of PDAC is its extensive tumor cell heterogene...

Oncogenic KRAS-dependent Stromal Interleukin-33 Directs the Pancreatic Microenvironment to Promote Tumor Growth

The Role of IL-33 in Promoting Tumor Growth in Pancreatic Cancer Tissue and its Potential as a Therapeutic Target Background Introduction Pancreatic Cancer (PDA) is one of the most lethal malignancies worldwide, characterized by rapid clinical progression and poor treatment responses, with a five-year survival rate of only 13%. In the United States...

The N6-Methyladenosine Epitranscriptomic Landscape of Lung Adenocarcinoma

The N6-Methyladenosine Epitranscriptomic Landscape of Lung Adenocarcinoma

The Epitranscriptomic Landscape of N6-Methyladenosine Modification in Lung Adenocarcinoma Background Lung cancer is one of the most common cancers globally and a leading cause of cancer-related deaths. Non-small cell lung cancer (NSCLC) accounts for about 80%-85% of all lung cancer cases, among which lung adenocarcinoma (LUAD) is of particular conc...

ZNF397 Deficiency Triggers TET2-driven Lineage Plasticity and AR-targeted Therapy Resistance in Prostate Cancer

ZNF397 Deficiency Triggers TET2-driven Lineage Plasticity and AR-targeted Therapy Resistance in Prostate Cancer

ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer Academic Background and Research Motivation Existing research evidence suggests that cancer cell lineage plasticity and epigenetic reprogramming enable them to evade lineage-dependent targeted therapy by adopting lineage plasticity. Howev...

CD28 Costimulation Augments CAR Signaling in NK Cells via the Lck/CD3ζ/ZAP70 Signaling Axis

The Costimulatory Role of CD28 Enhances the Function of CAR-NK Cells through the LCK/CD3ζ/ZAP70 Signaling Axis Research Background and Objective Chimeric Antigen Receptor (CAR) T-cell therapy has shown significant effects in treating certain advanced cancer patients. However, CAR-T cell therapy has many limitations, such as high cost, complex prepa...

CRISPR dependency screens in primary hematopoietic stem cells identify KDM3B as a genotype-specific vulnerability in IDH2- and TET2-mutant cells

CRISPR-Dependent Screening in Primary Hematopoietic Stem Cells Identifies KDM3B as Specific Susceptibility for IDH2 and TET2 Mutant Genotypes Background and Significance Clonal Hematopoiesis (CH) refers to the abnormal growth of genetically distinct subclones of cells initiated by specific mutations in Hematopoietic Stem Cells (HSCs). This phenomen...